RASSF1 and cancer: In the meta-analysis, the promoter methylation of RASSF1A was related to HCC risk in the cancer samples relative to the controls (OR = 31.05, 95% CI = 13.73–70.20, P < 0.001); in addition, a high heterogeneity level was detected across the various articles (I2 = 79.6%, P = 0.000).